Lifecore Biomedical (NASDAQ:LFCR) Stock Dropped to Hold by Craig Hallum

Posted by Brian Himes on Sep 30th, 2026

Craig Hallum downgraded shares of Lifecore Biomedical (NASDAQ:LFCR – Free Report) from a strong-buy rating to a hold rating in a report released on Monday,Zacks reports.

A number of other research firms also recently issued reports on LFCR. Weiss Ratings raised shares of Lifecore Biomedical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 9th. Zacks Research raised shares of Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Wall Street Zen upgraded shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Barrington Research cut shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research note on Tuesday. Finally, William Blair downgraded shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research report on Monday. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $6.50.

View Our Latest Report on Lifecore Biomedical

Lifecore Biomedical Stock Performance

LFCR stock opened at $6.59 on Monday. Lifecore Biomedical has a fifty-two week low of $3.63 and a fifty-two week high of $8.98. The business’s 50-day moving average is $4.54 and its two-hundred day moving average is $4.77. The company has a market cap of $249.43 million, a price-to-earnings ratio of -6.16 and a beta of 1.08.

Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19). The firm had revenue of $34.17 million for the quarter, compared to the consensus estimate of $34.18 million. Equities analysts predict that Lifecore Biomedical will post -1.02 earnings per share for the current year.

Institutional Trading of Lifecore Biomedical

Several institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in Lifecore Biomedical during the 1st quarter valued at approximately $64,000. Deutsche Bank AG bought a new position in Lifecore Biomedical in the 2nd quarter worth approximately $137,000. Bank of America Corp DE boosted its stake in Lifecore Biomedical by 64.4% in the 1st quarter. Bank of America Corp DE now owns 43,298 shares of the company’s stock worth $161,000 after purchasing an additional 16,961 shares during the period. Wittenberg Investment Management Inc. grew its holdings in Lifecore Biomedical by 26.1% during the 4th quarter. Wittenberg Investment Management Inc. now owns 21,723 shares of the company’s stock valued at $178,000 after buying an additional 4,500 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Lifecore Biomedical during the second quarter valued at approximately $353,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Trending Headlines about Lifecore Biomedical

Here are the key news stories impacting Lifecore Biomedical this week:

Positive Sentiment: Acquisition provides a defined cash value and potential upside. Webster Equity Partners will acquire Lifecore for $6.28 per common share in cash, a 49.5% premium to the unaffected price. Shareholders will also receive non-tradable contingent value rights (CVRs) tied to performance milestones, with potential aggregate payments of up to $160 million and total consideration of as much as $9.67 per common equivalent. The transaction is valued at up to approximately $663.7 million and is expected to support Lifecore’s growth objectives. Lifecore Biomedical to Be Acquired by Webster Equity Partners
Neutral Sentiment: Merger-related trading is likely limiting fundamental valuation signals. With the company expected to become privately held, investors are focusing primarily on deal completion, the $6.28 cash consideration and the value—and uncertainty—of the CVRs rather than on longer-term earnings prospects. Lifecore’s stock has recently traded around the transaction terms, with the CVRs creating potential additional value but no guaranteed payment. Lifecore agrees to acquisition with CVRs up to $160 million
Negative Sentiment: Analysts are turning more cautious. Craig Hallum downgraded Lifecore from “strong buy” to “hold,” while William Blair lowered its rating from “outperform” to “hold” or “market perform.” The revisions likely reflect limited upside to the cash offer and the uncertainty surrounding completion of the acquisition. William Blair Downgrades Lifecore Biomedical to Market Perform
Negative Sentiment: Shareholder investigations add deal risk. Several law firms are examining whether Lifecore’s board obtained a fair price, conducted an adequate sale process and properly protected shareholders. These reviews could create legal costs, delay the transaction or encourage changes to the deal terms, although they do not necessarily indicate wrongdoing. Brodsky and Smith shareholder investigation

Lifecore Biomedical Company Profile

(Get Free Report)

Lifecore Biomedical, Inc is a contract development and manufacturing organization (CDMO) that provides services to pharmaceutical, biotechnology and medical device companies. The company specializes in complex sterile injectable products and supports customers through product development, process development, manufacturing, aseptic filling, packaging and related regulatory services.

Lifecore’s capabilities include the production of injectable products using fermentation and other specialized manufacturing processes.